Case Report: Successful Stabilization of Marburg Variant Multiple Sclerosis With Ocrelizumab Following High-Dose Cyclophosphamide Rescue
The Marburg variant of multiple sclerosis (Marburg MS) is the most aggressive form of MS, often leading to death soon after onset. Here we describe the case of a 26-year-old Marburg MS patient presenting with severe neurological deficits requiring intensive care. In spite of more than 100 gadolinium...
Main Authors: | Valeria Koska, Moritz Förster, Katja Brouzou, Maryam Hatami, Ercan Arat, Ahmet Aytulun, Philipp Albrecht, Orhan Aktas, Patrick Küry, Sven G. Meuth, David Kremer |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-06-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2021.696807/full |
Similar Items
-
Ocrelizumab quantitation by liquid chromatography-tandem mass spectrometry
by: Erik I. Hallin, et al.
Published: (2022-08-01) -
Evaluation of BAFF, APRIL and CD40L in Ocrelizumab-Treated pwMS and Infectious Risk
by: Maria Antonella Zingaropoli, et al.
Published: (2023-04-01) -
Patient Monitoring during Treatment with Ocrelizumab and Rituximab (ORP-49)
by: Nazanin Razazian
Published: (2023-01-01) -
Recurrent Fulminant Tumefactive Demyelination With Marburg-Like Features and Atypical Presentation: Therapeutic Dilemmas and Review of Literature
by: Aigli G. Vakrakou, et al.
Published: (2020-06-01) -
OCRELIZUMAB IN THE TREATMENT OF PRIMARY-PROGRESSIVE MULTIPLE SCLEROSIS
by: E. V. Popova
Published: (2018-02-01)